Astellas Pharma Europe Limited
Chertsey, England (ots/PRNewswire) - Experts say the knock-on effect of lack of planning for later life, as highlighted in poll conducted for this year's ASTELLAS INNOVATION DEBATE[TM],will further impact upon stretched NHS resources Results from a new survey for the annual Astellas Innovation Debate have ...
Chertsey, England (ots/PRNewswire) - Poll conducted in advance of this year's ASTELLAS INNOVATION DEBATE(TM) also demonstrates public are open to an additional 'health tax' to support improved NHS services, but clinicians fear additional charges will hit the poorest hardest Although the NHS is ranked as one of the ...
Astellas Pharma Europe Limited
Chertsey, England (ots/PRNewswire) - - For Healthcare and Business Media - Approval allows for more flexible approach to 8% capsaicin patch treatment of peripheralneuropathic pain The European Commission (EC) has approved expanded options for pre-treatment prior to use of QUTENZA (8% capsaicin patch). Before ...
Astellas Pharma Europe Limited
Chertsey, England (ots/PRNewswire) - A new treatment, BETMIGA(TM) (mirabegron) has received approval from the European Commission (EC) for the treatment of overactive bladder (OAB) symptoms in adults.[1] Mirabegron represents the first new class of oral treatment in OAB for over 30 years. Currently around half of patients discontinue OAB treatment after only three ...
Astellas Pharma Europe Limited
Chertsey, England (ots/PRNewswire) - Spectacular New Facilities, in Chertsey, Designed by Sir Norman Foster Astellas Pharma Europe Ltd. (APEL), the European Headquarters of Tokyo-based Astellas Pharma Inc., one of the world's top 20 pharmaceutical companies, today formally opens its new office in Hillswood Business Park, Chertsey. To accommodate the company's ...
Astellas Pharma Europe Limited
Chertsey, England (ots/PRNewswire) - ASTELLAS PHARMA EUROPE Ltd. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a marketing authorisation for BETMIGA[TM] (mirabegron) for the symptomatic treatment of urgency, increased micturition ...
